Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

MBCProject_0243_T2_RNA

— · C

2f84af03-af0b-5e43-8f31-20520a93c2be

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
C
subtype
C

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MYC_TARGETS_V2+0.560
  • E2F_TARGETS+0.470
  • CHOLESTEROL_HOMEOSTASIS+0.420
  • MTORC1_SIGNALING+0.420
  • G2M_CHECKPOINT+0.380
  • MYC_TARGETS_V1+0.380
  • GLYCOLYSIS+0.360
  • OXIDATIVE_PHOSPHORYLATION+0.360
  • PANCREAS_BETA_CELLS+0.290
  • UNFOLDED_PROTEIN_RESPONSE+0.290

Top 10 suppressed

  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.450
  • ALLOGRAFT_REJECTION-0.410
  • INTERFERON_GAMMA_RESPONSE-0.360
  • IL6_JAK_STAT3_SIGNALING-0.340
  • TNFA_SIGNALING_VIA_NFKB-0.330
  • TGF_BETA_SIGNALING-0.320
  • UV_RESPONSE_DN-0.310
  • ANGIOGENESIS-0.290
  • KRAS_SIGNALING_UP-0.290
  • NOTCH_SIGNALING-0.280

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR10900021
melanoma-umap@29
——0.887
2AUR-AFUM-TTM1-A-1-1-R-A743-41
breast-umap@18
—E0.882
3TCGA-33-4532-01A-01R-1201-07
lung-landscapes@6
—cohortSQ20.876
4TCGA-21-1075-01A-01R-0692-07
lung-landscapes@6
—cohortSQ20.872
5TCGA-85-8354-01A-31R-2326-07
lung-landscapes@6
—cohortSQ20.872
6SRR35579804
breast-umap@18
—C0.870
7C3N-03204
lung-landscapes@6
—cohortSQ20.868
8SRR8613799
breast-umap@18
—E0.868
9TCGA-60-2722-01A-01R-0851-07
lung-landscapes@6
—cohortSQ20.868
10BS_YETBN0RQ
medullo-epn-umap@date-based
MedMedulloblastoma0.867

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 25 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MYC_TARGETS_V20.560Idelalisib— uncovered
E2F_TARGETS0.470Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.420Remibrutinib— uncovered
MTORC1_SIGNALING0.420Inavolisib— uncovered
G2M_CHECKPOINT0.380Inavolisib— uncovered
MYC_TARGETS_V10.380Inavolisib— uncovered
GLYCOLYSIS0.360Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.360Remibrutinib— uncovered
PANCREAS_BETA_CELLS0.290Cobimetinib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.290Idelalisib— uncovered
PEROXISOME0.250Idelalisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.230Inavolisib— uncovered
ADIPOGENESIS0.210Inavolisib— uncovered
FATTY_ACID_METABOLISM0.170Inavolisib— uncovered
HEDGEHOG_SIGNALING0.170Inavolisib— uncovered
SPERMATOGENESIS0.170Inavolisib— uncovered
MITOTIC_SPINDLE0.160Inavolisib— uncovered
DNA_REPAIR0.130Idelalisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.100Inavolisib— uncovered
UV_RESPONSE_UP0.100Idelalisib— uncovered